20 Biggest Publicly Traded Biotech Companies

3. Johnson and Johnson 

Market Cap: $369.42 Billion 

In 2021, Johnson & Johnson received FDA approval for two new products: RYBRVANTTM (amivantamab-vmjw), the first targeted treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations, and PONVORYTM (ponesimod) to treat adults with relapsing forms of multiple sclerosis. In Q1 2024, their total sales were $21.38 billion, a 2.34% increase year-over-year and their net income was $5.35 billion.